Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) – a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs – today announced an exciting new partnership with Celltrion for the development of RT-111, a groundbreaking oral ustekinumab biosimilar. This could be a major breakthrough for the biologics industry, delivering a drug that has been traditionally hard to administer in a new, convenient way.
Celltrion and Rani have come together to form an exclusive partnership – Rani has been granted exclusive rights to use Celltrion’s CT-P43 biosimilar drug substance for the development and commercialization of RT-111, and Celltrion has been granted the right of first negotiation for worldwide rights to RT-111 following a Phase 1 clinical trial. This exciting collaboration promises to bring new and innovative treatments to those who need them.
Say goodbye to needles and syringes! Rani has developed an innovative and revolutionary oral delivery technology known as the RaniPill™ capsule, which promises to revolutionize the way biologics and drugs are delivered. The RaniPill™ capsule offers a simple and painless alternative to traditional subcutaneous or intravenous injections, while delivering a bioavailability comparable to injection routes. Experience the convenience and comfort of RaniPill™ today!
We are thrilled to be teaming up with Celltrion, a leader in the development of biosimilars and biologics, for our RT-111 program. This collaboration is a testament to the success of our RaniPill oral drug delivery technology, which has already proven its efficacy in two successful Phase 1 trials of RT-101 and RT-102. We are honored to have Celltrion as our exclusive partner for ustekinumab biosimilar, and we look forward to presenting the results of our study soon, and expanding our relationship with Celltrion even further.
Celltrion is passionate about addressing the unmet needs of patients, and by partnering with Rani, they are striving to provide a much-needed alternative to painful injections – the RaniPill. With immense potential to apply this platform to other biologics, Celltrion’s Head of Medical Science Division, SungHyun Kim, is eager to see the impact this partnership will have on the lives of patients.
Rani Therapeutics is revolutionizing the way biologics and drugs are administered! Our proprietary and patented RaniPill™ capsules offer an alternative to subcutaneous injections or intravenous infusions, allowing patients to conveniently receive their treatments orally. We have conducted numerous preclinical and clinical studies to ensure safety, tolerability and bioavailability of RaniPill™ capsules, and are committed to making biologics and drugs more accessible and easier to take.
Rani Therapeutics is pleased to announce the expected initiation of a Phase 1 trial of RT-111 and the potential to broaden its partnership with Celltrion. This trial could open the door to the future commercialization of RT-111 and may even lead to Celltrion acquiring worldwide rights to the therapeutic. The RaniPill™ capsule has the potential to replace subcutaneous or intravenous injections and administer biologics or drugs with bioavailability comparable to subcutaneous injection. However, there are various risks and uncertainties associated with Rani’s business in general, the impact of the COVID-19 pandemic, and those described in Rani’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date.